Rachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields, an antimitotic treatment.
Rachel Grossman, MD, of Tel Aviv Sourasky Medical Center, discusses the treatment landscape for patients with newly diagnosed glioblastoma. She focuses on treatments utilizing tumor treating fields (TTFields) (Optune), an antimitotic treatment.
TTFields is a local, noninvasive treatment modality that delivers electric fields to the tumor site at low intensity, Grossman says.
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More